Merck antibody drug conjugate asset shows antitumor activity in phase 2
Source: SeekingAlpha
2025-05-30 11:17:18 ET
More on Merck
- Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
- Merck Proves Why It's Still A Top Pharma Pick
- Merck: Dividend Near A 12-Year High, But I Won't Buy - Here's Why
- Dividend Roundup: Nvidia, Merck, Lockheed Martin, Meta Platforms, and more
- MAHA report under attack for alleged fake sources, misinterpretations
Read the full article on Seeking Alpha
For further details see:
Merck antibody drug conjugate asset shows antitumor activity in phase 2
Militia Long/Short Equity ETF
NASDAQ: ORR
ORR Trading
-1.36% G/L:
$36.575 Last:
238,814 Volume:
$37.15 Open:
